bpc-157 legal status 2026 Exciting news for peptides coming out of today's committee hearing! The FDA Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC- 157 to the 503A Bulks List for use in compounding for Big news for the peptide

it was studied by Novo Nordisk and later Helsinn Therapeutics, including a Phase II trial for postoperative ileus, but development was discontinued for lack of efficacy

These powerful wellness tools support everything from immune function and cellular repair to collagen production and healthy aging, giving you the internal foundation your body needs to thrive

Final research-target dose 2.4 mg + 2.4 mg weekly Titration length ~16 weeks Trial duration 68 weeks (REDEFINE 1 / REDEFINE 2) Route Subcutaneous, once weekly Compound Delivery: 2.4 mg / 2.4 mg Maintenance Pre-blended vials simplify weekly administration to a single injection but lock the ratio at 1:1

GHK-Cu is well-suited for dermatological applications, while BPC-157 shows greater versatility for internal tissue repair

Accelerates Injury Recovery: BPC-157 speeds the repair of tendons, ligaments, and musclesmaking it popular with athletes and active individuals